Welcome to our dedicated page for VISKASE HOLDINGS SEC filings (Ticker: ENZN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Viskase Holdings, Inc. (ENZN) filings document the issuer's completed transition from Enzon Pharmaceuticals, Inc. to Viskase Holdings, including material-event reports on the merger closing, name change, exchange offer for Series C Non-Convertible Redeemable Preferred Stock, and related capital-structure disclosures.
The company's 8-K records also cover governance and ownership matters, including a Section 382 Rights Agreement, changes in certifying accountant, officer appointments, and amendments to the credit agreement of Viskase Companies, LLC, a wholly owned subsidiary. Other recurring disclosure areas include shareholder voting matters, material agreements, operating and financial results, risk factors, and legacy clinical or regulatory disclosures.
Viskase Holdings, Inc. director Dustin DeMaria submitted an initial statement of beneficial ownership as a Form 3 filing. The available data show no reported stock transactions and no derivative security positions in this filing, indicating it mainly serves as a baseline disclosure of his status as a director.
Viskase Holdings, Inc. filed an initial ownership report for officer Thomas Dale Davis. The Form 3 shows he directly holds 16,678 shares of Common Stock after the reported entry. This filing records his starting equity position as an insider, and does not reflect a new buy or sell transaction.
Viskase Holdings, Inc. insider Michael Blecic filed an initial ownership report on Form 3. The filing shows he directly holds 98 shares of Viskase common stock. This is a baseline disclosure of his equity position as an officer, with no new buy or sell transactions reported.
Viskase Holdings, Inc. executive Jan Stevens filed an initial ownership report on Form 3 for ticker ENZND. The filing lists Stevens as an officer (title referenced in the remarks section) but does not show any reportable transactions or specific share holdings at this time.
Viskase Holdings, Inc. filed an initial insider ownership report for company officer Robert Schouten. The Form 3 identifies him as an officer (title noted as “See Remarks”) but shows no reported transactions or derivative positions and does not list any specific share holdings in this data.
Viskase Holdings, Inc. officer Stender Mackenzie has filed an initial statement of beneficial ownership as a company insider. This filing lists Mackenzie as an officer but shows no reported share purchases, sales, or other transactions, and no derivative positions in the data provided.
Viskase Holdings, Inc. insider John Plescia filed an initial ownership report on Form 3. He is identified as an officer of the company, with his specific officer title referenced in the remarks section. The filing reports no transactions or current derivative holdings.
Viskase Holdings, Inc. director Peter Shea has filed an initial Form 3, which is a required statement of beneficial ownership for company insiders. The provided data shows no reportable transactions or derivative positions and does not list any specific shareholdings for this reporting person.
Viskase Holdings, Inc. director Colin Nicholas Kwak filed an initial Form 3, which is the required statement of beneficial ownership for insiders. The filing identifies him as a director of the company and does not report any insider transactions in the provided data.
Viskase Holdings, Inc., formerly Enzon Pharmaceuticals, completed its all-stock merger with Viskase Companies, Inc., making Viskase a wholly owned subsidiary that has been converted into Viskase Companies, LLC. The combined company will focus on Viskase’s meat and poultry casing business.
Enzon stockholders immediately before the merger own approximately 45% of the combined company’s common stock, while former Viskase stockholders own about 55%. Each share of Viskase common stock was converted into the right to receive 0.049118 shares of company common stock.
Before closing, 39,277 shares of Series C Preferred Stock held by Icahn Enterprises affiliates were exchanged into 5,658,396 common shares. The company changed its name to Viskase Holdings, Inc., eliminated its Series A-1 Junior Participating Preferred Stock designation, and its common stock is trading on the OTCQB under temporary symbol ENZND for 20 trading days.